Navigation Links
QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

QuatRx CEO will present an update on QuatRx clinical development programs including review of positive results from the Phase 3 pivotal trial for

Ophena(TM) (ospemifene)

ANN ARBOR, Mich., Jan. 4 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced that the company chief executive officer, Robert L. Zerbe, M.D., will be a presenter at the 26th Annual JP Morgan Healthcare Conference on Tuesday, January 8th, 2008, at 9:30 a.m., Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco from January 7 to 10, 2008.

Dr. Zerbe will present an update on clinical development programs at QuatRx including a review of the positive results from a pivotal phase 3 trial for Ophena(TM) (ospemifene) for the treatment of postmenopausal vaginal syndrome (PVS). Results of the pivotal phase 3 trial for Ophena(TM) were announced by QuatRx on January 3, 2008.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and two preclinical development programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Asord(TM) (becocalcidiol), a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, CollaGenex Pharmaceuticals, Inc. QuatRx's two preclinical small molecule programs are designed to address common endocrine disorders in women and men. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 Cambridge Semantics was ... week’s “Data Demonstration Day” on Capitol Hill, hosted by The ... Google, Microsoft and others to showcase how innovative data management ... and Transparency Act (DATA Act). , Originally introduced in 2011 ... and Sen. Mark Warner (D-VA ), the ...
(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... pioneering the development of disease modifying therapeutics for ... today the completion of its Series B financing, ... shares and warrants that would represent approximately $2.8M ... investors and new investors supported the raise. ...
(Date:5/22/2013)... May 22, 2013  Superior Controls, Inc. has ... by Business NH Magazine.  For the past 22 ... that distinguish themselves with extraordinary business and civic ... receive this honor," said Rick Pierro ... any recognition, this award is a reflection of ...
(Date:5/22/2013)... Basel, Switzerland (PRWEB) May 22, 2013 ... solutions for industrial biotechnology, drug discovery, and life ... Genedata Selector ™ as its bioinformatics ... its production-relevant organisms. Genedata will provide AB Enzymes, ... manufacturers, with a hosted solution of Genedata Selector ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:5/21/2013)... to a whale entangled in fishing gear, scientists showed ... whale,s diving and swimming behavior. The monitoring revealed how ... depletes their energy as they drag gear for months ... , The scientists in this entanglement response suction-cupped a ... North Atlantic right whale called Eg 3911. The Dtag, ...
(Date:5/21/2013)... a new method for delivering molecules into single, ... surface. The technique could find applications in drug ... Bulk electroporation a technique used to deliver ... cell membrane that are caused by exposing them ... method of cell transfection. (Cell transfection is the ...
(Date:5/21/2013)... Think keeping in shape is an uphill battle? Try ... and prolonged weightlessness withers muscle and bone. , That,s ... will address with a new three-year, $1.2 million grant ... to exercise during multiyear exploratory missions. , "You could ... if you can,t get them to stick to it, ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2
... A novel bacterium that has been trapped more than three ... years, may hold clues as to what life forms might ... a team of scientists from Pennsylvania State University report finding ... , in the current issue of the International Journal ...
... -- Begins in Houston , , HOUSTON, June 10 ... of Houston Center for ... Technology , announce today their agreement for the ... for the U.S. Gulf Region. This Center will house all ...
... be anymore waiting in the dark at this campus bus ... group of engineering researchers at McMaster University has been installed ... The researchers are also hoping that the prototype will help ... shelter is located on the west side of University Avenue ...
Cached Biology News:A tiny frozen microbe may hold clues to extraterrestrial life 2University of Houston Site of Regional Center of Excellence 2Flexible solar strips light up campus bus shelter 2
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
NORMAL DONOR DONKEY SERUM...
... 301 Power Supply, 1. 300 V, ... or constant current modes.Single-unit increments in ... reproducibility.Suitable for submarine, mini vertical, and ... as semidry and mini tank blotting ...
B3-1...
Biology Products: